Baroreflex activation is highlighted as a potential novel therapy for heart failure regardless of left ventricular ejection fraction.
It is known that abnormal sympathoexcitation is involved in the pathogenesis of chronic heart failure, and the sympathetic nerve activity is mainly and quickly regulated by baroreflex [1]. Interestingly, the arterial baroreflex is impaired both in heart failure with reduced left ventricular ejection fraction (HFrEF) and with preserved left ventricular ejection fraction (HFpEF) [1–5]. The arterial baroreflex system is an important and powerful regulator of the stressed blood volume and systemic blood pressure [6–8].
No takes yet. Share an insight, caveat, or question.
Takuya Kishi (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: